Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8NBH2
UPID:
KY_HUMAN
Alternative names:
-
Alternative UPACC:
Q8NBH2; B7Z1S4; Q6ZT15
Background:
Kyphoscoliosis peptidase, encoded by the gene with accession number Q8NBH2, plays a crucial role in muscle development and neuromuscular junction stability. It is believed to function as a cytoskeleton-associated protease, essential for normal muscle growth by potentially cleaving muscle-specific proteins such as FLNC.
Therapeutic significance:
The protein is implicated in Myopathy, myofibrillar, 7, a neuromuscular disorder marked by muscle weakness and atrophy. Understanding the role of Kyphoscoliosis peptidase could open doors to potential therapeutic strategies for treating this condition.